BiotechTV - News cover image

Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib

BiotechTV - News

00:00

Refractory patients, biomarkers, and regulatory opportunities

Richard says soquelitinib worked in prior‑therapy failures and that actionable biomarkers remain elusive.

Play episode from 12:44
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app